Cargando…
Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary
The use of immunosuppressive therapies for immune-mediated disease (IMD) is associated with an elevated risk of infections and related comorbidities. While many infectious diseases can generally be prevented by vaccines, immunization rates in this specific patient population remain suboptimal, due i...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785689/ https://www.ncbi.nlm.nih.gov/pubmed/31616855 http://dx.doi.org/10.1093/jcag/gwy069 |
_version_ | 1783457942167617536 |
---|---|
author | Papp, Kim A Haraoui, Boulos Kumar, Deepali Marshall, John K Bissonnette, Robert Bitton, Alain Bressler, Brian Gooderham, Melinda Ho, Vincent Jamal, Shahin Pope, Janet E Steinhart, A Hillary Vinh, Donald C Wade, John |
author_facet | Papp, Kim A Haraoui, Boulos Kumar, Deepali Marshall, John K Bissonnette, Robert Bitton, Alain Bressler, Brian Gooderham, Melinda Ho, Vincent Jamal, Shahin Pope, Janet E Steinhart, A Hillary Vinh, Donald C Wade, John |
author_sort | Papp, Kim A |
collection | PubMed |
description | The use of immunosuppressive therapies for immune-mediated disease (IMD) is associated with an elevated risk of infections and related comorbidities. While many infectious diseases can generally be prevented by vaccines, immunization rates in this specific patient population remain suboptimal, due in part to uncertainty about their efficacy or safety under these clinical situations. To address this concern, a multidisciplinary group of Canadian physicians with expertise in dermatology, gastroenterology, infectious diseases and rheumatology developed evidence-based clinical guidelines on vaccinations featuring 13 statements that are aimed at reducing the risk of preventable infections in individuals exposed to immunosuppressive agents. |
format | Online Article Text |
id | pubmed-6785689 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-67856892019-10-15 Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary Papp, Kim A Haraoui, Boulos Kumar, Deepali Marshall, John K Bissonnette, Robert Bitton, Alain Bressler, Brian Gooderham, Melinda Ho, Vincent Jamal, Shahin Pope, Janet E Steinhart, A Hillary Vinh, Donald C Wade, John J Can Assoc Gastroenterol Original Articles The use of immunosuppressive therapies for immune-mediated disease (IMD) is associated with an elevated risk of infections and related comorbidities. While many infectious diseases can generally be prevented by vaccines, immunization rates in this specific patient population remain suboptimal, due in part to uncertainty about their efficacy or safety under these clinical situations. To address this concern, a multidisciplinary group of Canadian physicians with expertise in dermatology, gastroenterology, infectious diseases and rheumatology developed evidence-based clinical guidelines on vaccinations featuring 13 statements that are aimed at reducing the risk of preventable infections in individuals exposed to immunosuppressive agents. Oxford University Press 2019-12 2019-02-01 /pmc/articles/PMC6785689/ /pubmed/31616855 http://dx.doi.org/10.1093/jcag/gwy069 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Articles Papp, Kim A Haraoui, Boulos Kumar, Deepali Marshall, John K Bissonnette, Robert Bitton, Alain Bressler, Brian Gooderham, Melinda Ho, Vincent Jamal, Shahin Pope, Janet E Steinhart, A Hillary Vinh, Donald C Wade, John Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary |
title | Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary |
title_full | Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary |
title_fullStr | Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary |
title_full_unstemmed | Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary |
title_short | Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary |
title_sort | vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies—executive summary |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785689/ https://www.ncbi.nlm.nih.gov/pubmed/31616855 http://dx.doi.org/10.1093/jcag/gwy069 |
work_keys_str_mv | AT pappkima vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary AT haraouiboulos vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary AT kumardeepali vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary AT marshalljohnk vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary AT bissonnetterobert vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary AT bittonalain vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary AT bresslerbrian vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary AT gooderhammelinda vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary AT hovincent vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary AT jamalshahin vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary AT popejanete vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary AT steinhartahillary vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary AT vinhdonaldc vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary AT wadejohn vaccinationguidelinesforpatientswithimmunemediateddisordersonimmunosuppressivetherapiesexecutivesummary |